ACXP logo

Acurx Pharmaceuticals, Inc.

ACXP
Healthcare|Biotechnology|US
$1.06
+0.11 (+12.09%)
DCF Value
$5.07
Tangible Book / Share
$1.91
Cash / Share
$2.50
Next Earnings Report
Nov 12, 2026
EPS est. -$0.45
Financing Filings (last 12 months)
10
Shelf registrations / offering prospectuses — latest Sep 17, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (1)

Sep 2027
Est. completion
P2Clostridium Difficile Infection Recurrence
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
NCT07513285n=20

Recent Press Releases

Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
Oct 26, 2026 · PRNewsWire
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
Oct 21, 2026 · PRNewsWire
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
Sep 29, 2026 · PRNewsWire
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs.
Sep 14, 2026 · PRNewsWire
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
Aug 17, 2026 · PRNewsWire
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
Aug 14, 2026 · PRNewsWire
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
Aug 12, 2026 · PRNewsWire
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
Aug 10, 2026 · PRNewsWire

SEC Filings (76)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 29, 20268-KMaterial eventDocumentIndex
Oct 16, 20268-KMaterial eventDocumentIndex
Sep 17, 2026EFFECTDocumentIndex
Sep 17, 2026424B3Offering prospectusDocumentIndex
Sep 8, 2026S-1IPO / offering registrationDocumentIndex
Sep 1, 2026ARSAnnual report to holdersDocumentIndex
Sep 1, 2026DEFA14AProxy / shareholder voteDocumentIndex
Sep 1, 2026DEF 14AProxy / shareholder voteDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
May 12, 2026424B3Offering prospectusDocumentIndex
May 12, 2026424B3Offering prospectusDocumentIndex
May 11, 2026EFFECTDocumentIndex
May 11, 2026EFFECTDocumentIndex
May 11, 202610-QQuarterly reportDocumentIndex
May 4, 2026S-1IPO / offering registrationDocumentIndex
May 4, 2026S-1IPO / offering registrationDocumentIndex
Apr 29, 2026DDocumentIndex
Apr 16, 20268-KMaterial eventDocumentIndex
Apr 16, 2026424B5Offering prospectusDocumentIndex
Mar 12, 2026S-8Employee stock planDocumentIndex
Mar 12, 202610-KAnnual reportDocumentIndex
Mar 9, 20268-KMaterial eventDocumentIndex
Feb 11, 2026EFFECTDocumentIndex
Feb 11, 2026424B3Offering prospectusDocumentIndex
Feb 2, 2026S-1IPO / offering registrationDocumentIndex
Jan 6, 2026EFFECTDocumentIndex
Dec 30, 2025S-3/AShelf registrationDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 12, 202510-QQuarterly reportDocumentIndex
Nov 10, 2025424B3Offering prospectusDocumentIndex
Oct 20, 2025S-1IPO / offering registrationDocumentIndex
Sep 22, 20258-KMaterial eventDocumentIndex
Sep 19, 20258-KMaterial eventDocumentIndex
Aug 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 11, 202510-QQuarterly reportDocumentIndex
Aug 5, 2025DEFA14AProxy / shareholder voteDocumentIndex
Aug 4, 2025DEF 14AProxy / shareholder voteDocumentIndex
Jul 31, 20258-KMaterial eventDocumentIndex
Jul 24, 2025PRE 14AProxy / shareholder voteDocumentIndex
Jul 23, 2025EFFECTDocumentIndex